ClinicalTrials.gg
RecruitingNCT06973863Updated Feb 13, 2026

A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of PEP08 in Advanced Solid Tumor, Solid Tumors and MTAP-deleted Solid Tumors, sponsored by PharmaEngine. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by PharmaEngine · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human clinical study of PEP08, a novel cancer therapy being evaluated both as monotherapy and in combination with other treatments in patients with advanced or metastatic solid tumors harboring MTAP deletion.

The study will be conducted in three parts, with Part 1 currently open for enrollment.

The primary objectives of the study are to:

  • Evaluate the safety and tolerability of PEP08, PK and PD
  • Determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
  • Assess preliminary signs of anti-tumor activity of PEP08

Key study questions include:

  • What is the recommended dose of PEP08 for further development?
  • Wht is the tolerable dose of PEP08 when administered alone or in combination?
  • Does PEP08 show early evidence of clinical activity in patients with MTAP-deleted tumors?

Participants in the study will:

  • Receive PEP08 alone or in combination with another anti-cancer agent, depending on the study part
  • Attend regular clinic visits for treatment administration, laboratory assessments, and tumor evaluations
  • Be enrolled in one of the following study phases over time:
  • - Part 1: Monotherapy dose escalation (currently enrolling).
  • - Parts 2 and 3 (monotherapy extension and combination therapy) will be activated in future protocol amendments.
02

Conditions studied

  • Advanced Solid Tumor
  • Solid Tumors
  • MTAP-deleted Solid Tumors
  • MTAP Deletion

Keywords

  • MTAP-del
  • PRMT5 inhibitor
03

In context

Lead sponsor

PharmaEngine is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be adults (≥18 years) and sign before undergoing any study-related procedures.
  • Eligible participants must have advanced or solid tumors that are not treatable with surgery or radiation, and show evidence of MTAP gene homozygous deletion or MTAP protein loss based on tumor tissue analysis.
  • Participants must have previously received standard treatment for their cancer type, and either experienced disease progression, be , or be intolerant to such therapies.
  • At least one is required, evaluated by standard imaging criteria ( v1.1).
  • Good general physical condition ( performance status 0-1 for dose escalation; broader range allowed for other parts).
  • Adequate function in key organs.
  • Able to swallow oral medication and comply with study requirements.
  • Women of and men with must use effective during and after the study.

Exclusion criteria

Exclusion Criteria:

  • Recent cancer treatment, immunotherapy, or drugs are not allowed before starting the study.
  • received shortly before treatment are not allowed.
  • Previous use of drugs with similar mechanisms to the study treatment is not allowed.
  • Active or unstable brain or meningeal , unless previously treated and stable without needing local treatment or high-dose .
  • History of other cancers within the last 2 years, unless low-risk and treated (e.g., in situ or certain skin cancers).
  • Uncontrolled disease-related complications (e.g., abnormal calcium levels, fluid buildup around organs).
  • Active , or C infections that are not well-controlled.
  • Ongoing serious infections or systemic conditions requiring isolation.
  • Significant heart disease, such as recent heart failure, ischemia, or arrhythmias.
  • History of severe digestive conditions or surgeries affecting drug absorption.
  • Recent major surgery.
  • Unresolved serious side effects from prior cancer treatment.
  • Currently pregnant or breastfeeding.
  • Poorly controlled blood pressure or lung conditions.
  • Other serious illnesses (e.g., severe anemia, psychiatric or social issues affecting study compliance).
  • Any condition that may pose a safety risk or interfere with the study, as judged by the investigator.
  • Known drug or substance abuse that may affect study participation.
  • Allergy to the study drug or any of its components.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    PEP08 monotherapy and expansion in advanced or metastatic solid tumors

    This arm of the study involves dose escalation to evaluate the tolerability and response of PEP08 monotherapy. Participants in this arm will receive daily dosing and be regularly monitored. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

    Drug: PEP08

Interventions

  • DrugPEP08

    PEP08 is an oral, potent, MTA-cooperative PRMT5 inhibitor.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events (AE)

    Time frame: Up to 2 years

  2. Number of Participants Experiencing Serious Adverse Events (SAE)

    Time frame: Up to 2 years

  3. Number of Patients who Experience Dose-Limiting Toxicity

    Time frame: 21 days

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    Time frame: Up to 6 days

  2. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 6 days

  3. Maximum observed plasma concentration (Cmin)

    Time frame: Up to 6 days

  4. Time to achieve maximal plasma concentration (Tmax)

    Time frame: Up to 6 days

  5. Terminal elimination half-life (t1/2)

    Time frame: Up to 6 days

  6. Objective Response Rate (ORR) per RECIST v1.1

    Time frame: Up to 2 years

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 15, 2025
StartActual
Aug 26, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2028
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06973863
Lead sponsor
PharmaEngine
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Aug 26, 2025
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Feb 13, 2026

Study contacts

Project Manager
Contact
hannie.yu@pharmaengine.com
+886 2 2515 8228 ext. ext 205

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion